Perspective Therapeutics/$CATX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Perspective Therapeutics
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
- Ticker
- $CATX
- Sector
- Health
- Primary listing
- AMEX
- Employees
- 165
- Headquarters
- Seattle, United States
CATX Metrics
BasicAdvanced
$90M
-
-$1.25
1.85
-
Price and volume
Market cap
$90M
Beta
1.85
52-week high
$6.16
52-week low
$0.78
Average daily volume
2.9M
Financial strength
Current ratio
6.609
Quick ratio
6.489
Long term debt to equity
0.009
Total debt to equity
0.012
Interest coverage (TTM)
-410.60%
Profitability
EBITDA (TTM)
-121.186
Gross margin (TTM)
-23,415.65%
Net profit margin (TTM)
-28,467.97%
Operating margin (TTM)
-30,619.07%
Effective tax rate (TTM)
0.68%
Management effectiveness
Return on assets (TTM)
-22.28%
Return on equity (TTM)
-39.57%
Valuation
Price to revenue (TTM)
179.754
Price to book
0.28
Price to tangible book (TTM)
0.32
Price to free cash flow (TTM)
-0.607
Free cash flow yield (TTM)
-164.84%
Free cash flow per share (TTM)
-1.3
Growth
Revenue change (TTM)
-66.88%
Earnings per share change (TTM)
-5.27%
3-year revenue growth (CAGR)
-20.73%
3-year earnings per share growth (CAGR)
9.58%
What the Analysts think about CATX
Analyst ratings (Buy, Hold, Sell) for Perspective Therapeutics stock.
Analyst projections of the future price of Perspective Therapeutics stock.
CATX Financial Performance
Revenues and expenses
CATX Earnings Performance
Company profitability
Upcoming events
No upcoming events
CATX News
AllArticlesVideos
Funds containing CATX
Fund name | Fund size | $CATX weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.00% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.